CAR-T Therapies Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Dr Grover discusses the background and findings of her study on anti-CD30 CAR-T therapy for patients with relapsed/refractory Hodgkin lymphoma.
View More
Ivana Bozic, PhD, highlights her study which evaluated the efficacy of patient preconditioning in the context of CAR T-cell therapy.
View More
Dr Martin Hutchings discusses his study on glofitamab, a bispecific antibody, in relapsed or refractory B-cell NHL.
View More
Premal Lulla, MBBS, discusses his team's study on the use of nonengineered T-cells for the treatment of patients with HL and NHL.
View More
Paolo Caimi, MD, discusses findings from a study examining the use of prophylactic tocilizumab prior to anti-CD19 CAR-T therapy for relapsed/refractory lymphoma.
View More
Mehdi Hamadani, MD, discusses an analysis evaluating the role of autologous transplant in relapsed DLBCL with newer therapies, specifically CAR T-cells.
View More
In this video, Dr Raje discusses the clinical significance of anti-BCMA CAR-T therapy with bb2121 in patients with relapsed or refractory MM.
View More
Peter Riedell, MD, discusses results from a multicenter retrospective analysis of outcomes and toxicities with commercial CAR-T therapies for relapsed and refractory aggressive B‑cell lymphomas.
View More
Lauren Pinter-Brown, MD, FACP, explains which patients with lymphoma should be referred to receive CAR T-cell therapy. 
View More
Stay in the know.
OncNet Newsletter